Weil advised DRI Healthcare Acquisitions LP in connection with its royalty financing agreement with Viridian Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases. Proceeds are expected to fund the anticipated commercial launches of Viridian’s veligrotug and VRDN-003 thyroid eye disease treatments.

The Weil team was led by David J. Cohen, Co-Managing Partner of Weil’s Miami office, and included associate Justin Kanoff; Banking & Finance partner Meredith Mackey; and Life Science Transactions & IP partner Kane Wishart.